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C linical practice guidelines (CPGs) are highly influen-tial within medicine, defining the standard of care formanyailments. Ideally, they shouldbebasedona com-
prehensive evaluation of available data and unbiased expert
opinion.1 However, financial conflicts of interest (FCOIs) be-
tween guideline authors and industry create the potential for
undue influence of for-profit companies inmedical practice.2
Published evidence on the effects of FCOIs on guideline
recommendations is limited,3 but suggests that authors with
industry FCOIs aremore likely to recommend specific drugs4
and assess clinical trial results more favorably.5 In addition,
FCOIs influence physician prescribing practices, as physi-
cians with FCOIs are more likely to prescribe brand-name
drugs.6 TheOpenPayments Provision (“SunshineAct”) of the
Affordable Care Act recently made public all FCOIs between
industry and US physicians, facilitating systematic study of
FCOIs and ending reliance on self-reporting.
Withinoncology, theNationalComprehensiveCancerCen-
ter (NCCN) guidelines influence clinician practice and define
which drugs are reimbursable throughMedicare.7 The goal of
this study is to quantify the presence and extent of FCOIs
among authors of recent NCCN guidelines for the treatment
of breast, colon, prostate, and lung cancer.
Methods
Since August, 2013 the Sunshine Act has required that all US
drug anddevicemanufacturers disclose transfers of financial
value greater than $10 to physicians and teaching hospitals.
IMPORTANCE Financial conflicts of interest (FCOIs) among authors of clinical practice
guidelines have the potential to influence treatment recommendations.
OBJECTIVE To quantify FCOIs with industry among authors of the National Comprehensive
Cancer Network (NCCN) guidelines.
DESIGN, SETTING, AND PARTICIPANTS We assessed FCOIs occurring during 2014 among NCCN
guideline authors in the United States. All were physician members of the NCCN guideline
committees for lung, breast, prostate, and colorectal cancer as of the end of 2014. The data
source for FCOIs was Open Payments, which is publically reported by the Centers for
Medicare andMedicaid Services. This study was cross-sectional.
MAIN OUTCOMES ANDMEASURES The proportion of NCCN authors having FCOIs with
industry; the average amount received from industry sources per author.
RESULTS Of 125 guideline authors, 108 (86%) had at least 1 reported FCOI. Authors received
an average of $10011 (range, $0-$106859) in general payments (GPs), which include
consulting, meals, lodging, and similar transfers of value, and $236066 (range
$0-$2 756 713) in industry research payments (RPs), including funding associated with clinical
trials. Approximately 84% of authors received GPs, while 47% received RPs. Eight (6%) had
FCOIs in excess of the $50000 net and/or $20000 single-companymaximums stipulated
by NCCN.
CONCLUSIONS AND RELEVANCE Among NCCN guideline authors, FCOIs involving RPs were of
greater value, while those involving GPs weremore prevalent. Although FCOIs may result
from engaging in important scholarship, FCOIs may still influence guideline authors in
counterproductive ways. Research is needed to understand how best to manage author
FCOIs during guideline creation.
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Payments are reported either as “general payments,” includ-
ing gifts, consultancy and/or speaker fees, meals, and invest-
ment interests,8 or as “research payments,” including “any
direct compensation, funding for coordination or implemen-
tation, or studyparticipant expense”9 related to preclinical re-
search,USFoodandDrugAdministrationphase1 to4trials, and
investigator-initiated studies.10
We identified the authors who were active on the NCCN
guideline panels for lung, colon, breast, and prostate cancer
as of the end of 2014. These were selected as the malignant
neoplasms with the highest incidence in the United States.
Using the public Open Payments database (https://www.cms
.gov/openpayments/), FCOIs for each author were manually
abstracted. We included all payments occurring in 2014,
excludeddisputedpayments,andcalculatedpaymentaverages
and ranges for general payments and researchpayments both
together andseparately.Authors activeonmultiple guidelines
were counted only once. In sensitivity analysis we excluded
FCOIs that fell below different dollar value thresholds (eg,
<$100),asphysicians receivingsuchpaymentsmaybeunaware
of and/or less influenced by such payments. The study was
reviewedby theUniversity ofNorthCarolinaOffice ofHuman
Research Ethics and was found not to constitute human
subjects research.
Results
Weidentified 125authors across the4guidelines, ofwhom108
(86%) had at least 1 reported FCOI, with no significant differ-
ences in frequency or monetary value of FCOIs among the 4
cancer types (eTable 1 in the Supplement). The total value of
FCOIs reported in2014among these authorswas $30287549,
representing $29036 127 in RPs and $1 251 422 in general pay-
ments (Table).
Authors received a mean of $10011 in general payments
(range, $0-$106 859) (Table). Most authors (70 [56%]) re-
ceived $1000 or more in general payments (Figure 1). These
results were not sensitive to the inclusion of low-value FCOIs
(eTable 2 in the Supplement).
Research paymentswere ofmuch highermonetary value
than general payments, but were less common among NCCN
guideline authors. Authors received ameanof $236066 in re-
search payments (range, $0-$2 756 713) (Table). Of the 125 au-
thors, 84% received 1 or more general payments from indus-
try while only 47% received any research payments. While a
substantialportionofauthors receivedgeneralpaymentsalone
without also receiving researchpayments, the reversewasnot
true; only 3 authors (2%) received research payments with-
out also receiving at least some general payments (Figure 2).
There were 8 authors (6%) whose FCOIs exceeded the
$50000net and/or $20000single-companymaximumstipu-
lated by the NCCN guideline policy.
Discussion
Through recent federal initiatives to increase transparency of
FCOIs between physicians and the pharmaceutical industry,
there has been growing awareness of anddebate over the role
and influence of FCOIs inmedicine. Somehave resisted blan-
ket condemnation of all apparent conflicts, many of which
represent important scholarly activity.11Others remain con-
cerned, given prior work suggesting that industry FCOIs can
influencephysicianprescribingbehavior,6 recommendations,4
and interpretation of clinical data.5
Our study demonstrates the high prevalence and signifi-
cant monetary value of FCOIs among oncology guideline au-
thors. Several findings are noteworthy. First, most of the
dollar value of industry FCOIswas contained in research pay-
ments. While these payments support research and are often
paid to thephysician’s institution, physicians accrueother, in-
direct benefits by procuring outside research funding. There-
fore, research payments aswell as general payments have the
potential to create conflicts of interest. More investigation is
needed on the relative influence of general payments and re-
search funding on physician practice and guideline recom-
mendations.
Second,wemust consider the reasons that FCOIs emerge
and their potential benefits. With the bulk of research fund-
ing coming from industry, accepting research funding is all but
Key Points
Question What is the prevalence of financial conflicts of interest
with industry among National Comprehensive Cancer Network
guideline authors?
Findings In this cross-sectional analysis of Open Payments data,
86% had financial conflicts of interest, including 84%who
accepted general payments and 47%who accepted research
payments.
Meaning The potential for undue influence of industry in
oncology clinical practice guidelines should be addressed.
Table. General Payments and Research Payments Received by NCCNGuideline Authors in 2014
Variable
Payments, Mean (Range), $
Generala Research
Authors receiving, No. (%) [N = 125] 105 (84) 59 (47)
Total received, all authors 1 251 422 29 036 127
Per author 10 011 (0-106 859) 236 066 (0-2 756 713)
Companies from which each author received
payment, No.
3.8 (0-19) 1.8 (0-13)
Value of payments from single company to
single author, $
2618 (2-39 863) 123 047 (17-1 823 352)
Abbreviation: NCCN, National
Comprehensive Cancer Network.
a Such as food, travel, lodging,
consultancy fees.
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mandatory for an academic clinical trialist. In addition, there
maybesocietalvalue inhavingphysicianswhobridgethespace
between academia and industry, advising on areas of medi-
cal need, and then furthering such ideas into clinical research
through involvement in research studies.
However, our data suggest that not all academic oncolo-
gists accrue FCOIs with industry as a result of research en-
deavors. A significant portion (39% of authors studied) ac-
cepted general payments in the absence of any research
payments to indicate active research participation.
Guideline-writingbodiesareawareofFCOIs,andsomehave
taken action to moderate the influence of potentially con-
flicted authors. For example, the American Society of Clinical
Oncology restricts authorswithFCOIs to less than50%of each
guidelinecommittee.12 Indeed, theNCCNguidelinespanels re-
cusememberswith“meaningful conflictsof interest” fromdis-
cussion on specific topics and require members not to exceed
annually $20000 in FCOIs with an individual corporation or
$50000 in total FCOIs.Our findings suggest thatmost, butnot
all, NCCN authors comply with these requirements.
Our studywas limited in thatOpenPayments collectsdata
onlyonphysicians, andsoFCOIsofnonphysicianNCCNguide-
line authors were not available; having such data would in-
crease the average and total payments to authors we re-
ported. While Open Payments data undergo a thorough
validationprocess, including anopportunity for physicians to
dispute reported payments before public release,13 there re-
mainways inwhich theymaybe imprecise or inaccurate. The
dispute process is difficult to navigate, potentially prevent-
ingphysicians fromcorrectingreportingerrors.14BecauseOpen
Payments is limited toUSphysicians, these findingswouldnot
begeneralizable outsideof theUnitedStates. In addition, phy-
sicians may have payments reported for participating in the
National Institutes ofHealth or cooperative group trials using
donated drugs,8 receiving grants from charitable organiza-
tions such as theConquer Cancer Foundation, or coauthoring
manuscripts,15withouthavinghaddirect interactionwith any
corporation.
Conclusions
Howbest tomanage the FCOIs in oncology practice and clini-
cal practice guidelines remains anareaof opendiscussionand
research. Practically, thehighprevalenceofFCOIs amongphy-
sician field experts makes identifying individuals without
FCOIs difficult, with the potential unwanted outcome of ex-
cluding valuable expertise. More research is needed to deter-
mine which kinds of relationships are more likely to produce
the unwanted consequence of physician bias to create ratio-
nal, evidence-basedpolicies that allow for theparticipationof
key clinical experts while managing real or perceived con-
flicts.Given theprevalenceofFCOIs reportedhere, finding the
answer to this question is critical.
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Oncology researchandclinical advancementsoften require fi-
nancial partnerships andcollaborationsbetween industry and
oncologyphysicians and researchers. These relationships be-
tweenoncology and industry are increasing, and concerns ex-
ist regarding the extent to
whichfinancial conflictsof in-
terest (FCOIs) can influence
medical decisions andphysi-
cian behavior.1,2 Thus, there is a pressing need to better un-
derstand the effects of FCOIs on both practicing oncologists
and academic researchers.
In this issueof JAMAOncology,Mitchell et al3 describe the
prevalence of FCOIs among authors of recent National Com-
prehensive Cancer Network (NCCN) guidelines. They found
that over 85% of NCCN guideline authors had at least 1 re-
portedFCOI,mostofwhichweregeneral payments, butnearly
half also receivedresearchpayments.Also in this issueof JAMA
Oncology, Boothby et al4 investigate FCOI disclosure among
video presentations from recent American Society of Clinical
Oncology (ASCO) annualmeetings. Theydetermined that the
duration of speaker disclosures often exceeded the range of
comprehension among most readers, questioning the effec-
tiveness of this policy. These accompanying articles under-
score the importance of further understanding FCOIs within
oncology.
Although FCOIs may create a potential risk for compro-
mised judgementamong researchers andunduebias fromout-
sidecommercial interests, therearealsopotentialpositivecon-
sequences associated with FCOIs. Collaboration between
industry and academic researchers may facilitate the devel-
opment of novel cancer therapies, a shared goal aligning the
interestsof industry, academia, andpatients. Inaddition,prior
work has demonstrated that FCOIs correlate with greater
prominenceof research abstracts accepted for presentation at
theASCOannualmeeting.1Whether this reflects bias in the in-
terpretation of the research and/or that industry seeks col-
laborationwithmore prominent researchers, or vice versa, is
unknown.Nevertheless, thismayhelpexplainwhysucha large
proportion of NCCN guideline authors report FCOIs. Recruit-
ers for both the NCCN guidelines and industry collaboration
would logicallyseekto forgerelationshipswith themostpromi-
nent researchers and experts in the field. However, the integ-
rity of scientific research and maintenance of trust in the re-
searchprocess requireongoingandrigorousscrutiny regarding
the methods for managing and/or prohibiting FCOIs.
BothASCO5and theNCCN6publicly report theirFCOIpoli-
cies, but consensus about howbest tomanage or prohibit po-
tential FCOIs is lacking. In addition, self-disclosure alonemay
result in anunderestimationof the trueprevalence of FCOIs.7
The reliance on self-reporting of FCOIs may now be less of a
concernwiththeadventof theOpenPaymentsProvision(“Sun-
shineAct”) of theAffordableCareAct. This allowsmedical or-
ganizations and professional societies to create FCOI disclo-
sure policies and use the public Open Payments database to
ensure members adhere to their policies. Importantly, these
FCOI policies need to be accessible, consistent, transparent,
and enforceable to facilitate adherence to the policies.2
The need for comprehensible and meaningful FCOI poli-
cies amongprofessional societies anduniversities is clear.His-
torically, the basis for most FCOI policies has relied solely on
disclosure of relationships. In the modern era, in which pub-
lic scrutiny of such relationships has never been higher, FCOI
policiesneedtogobeyondmeredisclosure toalso includeman-
agement (ie, enforcement of actions such as auditing or pro-
hibition) of relationships that are a cause for concern. For ex-
ample, ASCO’s FCOI policy contains requirements for general
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